Twist Bioscience Corp (TWST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com11-19

Revenue: $84.7 million for Q4, a 27% increase year-over-year; $313 million for fiscal 2024, a 28% increase over fiscal 2023. Gross Margin: 45.1% for Q4; 42.6% for fiscal 2024, up from 36.6% in fiscal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484960870?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nv4PUpE7fniOOuvMB3TZSg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/876005bb7272ec6a14d7cce2dfd4140a","is_english":true,"pubTime":"2024-11-19 15:02","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484960870","market":"us","top_or_hot":-1,"title":"Twist Bioscience Corp (TWST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $84.7 million for Q4, a 27% increase year-over-year; $313 million for fiscal 2024, a 28% increase over fiscal 2023.\nGross Margin: 45.1% for Q4; 42.6% for fiscal 2024, up from 36.6% in fiscal ...</p>\n\n<a href=\"https://finance.yahoo.com/news/twist-bioscience-corp-twst-q4-070214461.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twist Bioscience Corp (TWST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwist Bioscience Corp (TWST) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 15:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/twist-bioscience-corp-twst-q4-070214461.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $84.7 million for Q4, a 27% increase year-over-year; $313 million for fiscal 2024, a 28% increase over fiscal 2023.\nGross Margin: 45.1% for Q4; 42.6% for fiscal 2024, up from 36.6% in fiscal ...</p>\n\n<a href=\"https://finance.yahoo.com/news/twist-bioscience-corp-twst-q4-070214461.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"https://finance.yahoo.com/news/twist-bioscience-corp-twst-q4-070214461.html","article_id":"2484960870","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nv4PUpE7fniOOuvMB3TZSg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/876005bb7272ec6a14d7cce2dfd4140a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484960870","pubTimestamp":1731999734,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $84.7 million for Q4, a 27% increase year-over-year; $313 million for fiscal 2024, a 28% increase over fiscal 2023.Gross Margin: 45.1% for Q4; 42.6% for fiscal 2024, up from 36.6% in fiscal 2023.Cash Balance: $276.4 million as of September 30, 2024.SynBio Revenue: $33.9 million for Q4, a 28% increase year-over-year; $123.5 million for fiscal 2024, a 26% increase over fiscal 2023.NGS Revenue: $45.5 million for Q4, a 23% increase year-over-year; $169.1 million for fiscal 2024, a 37% increase over fiscal 2023.Biopharma Revenue: $5.3 million for Q4; $20.3 million for fiscal 2024.Adjusted EBITDA: Loss of approximately $17 million for Q4; loss of approximately $93.5 million for fiscal 2024, an improvement of $54 million over fiscal 2023.Operating Expenses: $74.3 million for Q4; $354 million for fiscal 2024, including a $45 million impairment charge.Capital Expenditures: $5 million for fiscal 2024, a reduction from $28 million in fiscal 2023.Orders: $88.2 million for Q4, a 24% increa","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"Twist Bioscience Corp(TWST)2024年第四季度收益看涨期权亮点：创纪录的收入增长和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"Revenue: $84.7 million for Q4, a 27% increase year-over-year; $313 million for fiscal 2024, a 28% increase over fiscal 2023.\nGross Margin: 45.1% for Q4; 42.6% for fiscal 2024, up from 36.6% in fiscal 2023.\nCash Balance: $276.4 million as of September 30, 2024.\nSynBio Revenue: $33.9 million for Q4, a 28% increase year-over-year; $123.5 million for fiscal 2024, a 26% increase over fiscal 2023.\nNGS Revenue: $45.5 million for Q4, a 23% increase year-over-year; $169.1 million for fiscal 2024, a 37% increase over fiscal 2023.\nBiopharma Revenue: $5.3 million for Q4; $20.3 million for fiscal 2024.\nAdjusted EBITDA: Loss of approximately $17 million for Q4; loss of approximately $93.5 million for fiscal 2024, an improvement of $54 million over fiscal 2023.\nOperating Expenses: $74.3 million for Q4; $354 million for fiscal 2024, including a $45 million impairment charge.\nCapital Expenditures: $5 million for fiscal 2024, a reduction from $28 million in fiscal 2023.\nOrders: $88.2 million for Q4, a 24% increase year-over-year; $344.2 million for fiscal 2024.\n\n\nWarning! GuruFocus has detected 3 Warning Signs with TWST.\n\nRelease Date: November 18, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nTwist Bioscience Corp (NASDAQ:TWST) reported a record quarter in revenue and margin growth, with a 27% year-over-year increase in revenue to $84.7 million.\nThe company achieved a gross margin of 45.1% for the quarter, exceeding guidance and demonstrating significant improvement from the previous year.\nTwist Bioscience Corp (NASDAQ:TWST) has successfully expanded its customer base to over 3,500 customers across multiple industries, indicating strong market penetration.\nThe company's Express product portfolio and NGS tools portfolio have shown continued growth, contributing positively to revenue and market share.\nTwist Bioscience Corp (NASDAQ:TWST) is on track to reach adjusted EBITDA breakeven, with a focus on becoming cash flow positive and driving profitable growth.\n\n Negative Points \n\nDespite revenue growth, Twist Bioscience Corp (NASDAQ:TWST) reported an adjusted EBITDA loss of approximately $17 million for the fourth quarter.\nOperating expenses, excluding cost of revenues, remained high at $74.3 million for the quarter, highlighting challenges in cost management.\nThe Biopharma segment, while showing some growth, remains a small portion of overall revenue and faces challenges in commercial execution.\nThe company faces potential headwinds from competitors manufacturing outside the US, which could impact market dynamics.\nTwist Bioscience Corp (NASDAQ:TWST) has not assumed a ramp in MRD (minimal residual disease) in its 2025 guidance, indicating uncertainty in this growth area.\n\n Q & A Highlights \nQ: Can you provide insights on the trends for Express Genes and new products within the SynBio mix throughout the year and specifically in Q4? Additionally, how should we think about OpEx trends for R&D and SG&A next year? A: We expect modest, inflationary increases in OpEx, with a significant portion in Q1 due to annual merit and bonus increases. For Express Genes, we anticipate continued sequential improvement in gross margin each quarter, aiming for a 50% gross margin by Q4. - Adam Laponis, CFO\nQ: What is Twist's exposure to NIH budgets, and have you noticed any changes in competitive behavior or market share gains? A: Our exposure to NIH budgets is minimal, less than 1%, presenting an opportunity for market share growth. All our DNA is manufactured in the US, which is increasingly important to customers concerned about supply chain security, providing us a competitive advantage. - Emily Leproust, CEO\nQ: How do new innovations in next-gen sequencing (NGS) affect Twist's revenue opportunities? A: These innovations are positive for us as they emphasize quality and performance, areas where we excel. Our rapid R&D capabilities allow us to stay at the forefront, leveraging both innovation and commercial execution to grow revenue. - Emily Leproust, CEO\nQ: Could you elaborate on the assumptions for the 2025 guidance, particularly for NGS and SynBio markets? A: We have not assumed an MRD ramp but expect continued improvement in liquid biopsy and customer base expansion. For SynBio, we anticipate growth in net new accounts and Express Genes, contributing to sequential gross margin improvement throughout the year. - Adam Laponis, CFO\nQ: Can you provide an update on the DNA storage initiative and any associated milestones or customer engagements? A: We are focused on developing a terabyte-scale product using enzymatic chemistry for cost and sustainability benefits. While it's early to discuss customers, significant progress is being made in technology development. - Emily Leproust, CEO\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484960870"}